$3.31
-7.77-70.13%
Last update: Oct 30, 7:58 PM
ProMIS Neurosciences Inc (PMN) Stock Price, Quote, News & History
PMNNASDAQ
ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.
You can purchase shares of ProMIS Neurosciences (NASDAQ:PMN) through any online brokerage.
Other companies in ProMIS Neurosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
ProMIS Neurosciences has a consensus price target of $52.33.
The stock price for ProMIS Neurosciences (NASDAQ: PMN) is $3.77 last updated October 30, 2026 at 7:58 PM EDT.
There are no upcoming dividends for ProMIS Neurosciences.
ProMIS Neurosciences does not have any upcoming earnings scheduled.
There is no upcoming split for ProMIS Neurosciences.
ProMIS Neurosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic...
